- Eculizumab, sold
under the
brand name
Soliris among others, is a
recombinant humanized monoclonal antibody used to
treat paroxysmal nocturnal hemoglobinuria...
-
orphan drugs to
treat rare diseases. Its
products include eculizumab (
Soliris) and
ravulizumab (Ultomiris), both used to
treat the rare
disorders of...
- anti–factor H antibodies).: 1933
Prior to
availability of
eculizumab (
Soliris) and
ravulizumab (Ultomiris), an
estimated 33–40% of
patients developed...
- the
European Union in
April 2024. Eculizumab, sold
under the
brand name
Soliris among others, is a
recombinant humanized monoclonal antibody used to treat...
-
hemolysis in
people treated with
eculizumab (
Soliris). The
highest risk was when
individuals "received a dose of
Soliris within 2 w****s
after being vaccinated...
-
antibodies patients with aHUS had an
extremely poor prognosis.
Eculizumab (
Soliris®,
Alexion Pharmaceuticals, Inc., Boston, MA, USA) is a
humanized monoclonal...
-
solasulfone (INN)
Solatene Solfoton Solganal solifenacin succinate (USAN)
Soliris solithromycin (USAN, INN)
solpecainol (INN) Solu-Cortef Solu-Medrol Solugel...
- aflibercept-jbvf/Yesafili aflibercept/Eylea May 2024 eculizumab-aeeb/Bkemv eculizumab/
Soliris June 2024 ustekinumab-ttwe/Pyzchiva ustekinumab/Stelara June 2024 filgrastim-txid/Nypozi...
- (brand)
Brand Date of FDA
approval Mechanism of
action Note
Eculizumab Soliris 2019
Monoclonal antibody against complement protein C5
Approved for AQP4-IgG-positive...
-
Ecromeximab mab
chimeric GD3
ganglioside malignant melanoma Eculizumab Soliris mab
humanized C5 Y
paroxysmal nocturnal hemoglobinuria,
atypical hemolytic...
